Pill Protect®: The first clinically validated test for identifying women at risk of developing deep vein thrombosis (DVT) under contraceptive pills

Gene Predictis®, a Swiss precision medicine company, has completed an international clinical validation study for Pill Protect®, an innovative medical test that uses genetic data to identify women at risk of developing blood clots (thrombosis) when using contraceptive pills. The test was shown to identify over 8 times more women at risk than today standard of care, making Pill Protect® the best available test. Already proposed in Switzerland and reimbursed by the insurances, the test helps to identify women at risk of thrombotic disease and facilitate the decision process for medical doctors helping them to propose the most optimal and safest contraceptive pill/method for every woman.

Press release_Pill Protect_september 2015_ang